Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors

NCT01824875 is registered in ClinicalTrials.gov with ECOG-ACRIN Cancer Research Group as lead sponsor.

NCT NCT01824875
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01824875 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Lead sponsor
ECOG-ACRIN Cancer Research Group
Phase
Phase 2
Overall status
Completed
Start date
August 8, 2013
Completion date
May 26, 2026
Enrollment
144 (actual)
Sites
323

Conditions

As the registry lists them; a condition with its own page is linked.

gastrinoma, glucagonoma, insulinoma, islet cell carcinoma, pancreatic polypeptide tumor, recurrent islet cell carcinoma, somatostatinoma